ASH 2022 | The potential of bringing CAR-T therapy to MDS and challenges to overcome
Eric Padron
• 9 Dec 2022
Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses the possibility of bringing CAR-T therapy to myelodysplastic syndromes (MDS) and challenges in this space, including identification of suitable targets and overcoming the immunosuppressive tumor microenvironment. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
